Ceva Santé Animale, a French multinational veterinary pharmaceutical company, acquired veterinary biopharmaceutical and R&D activities of IDT Biologika, an innovative, privately-held company with nearly 100 years of experience in researching, developing, manufacturing and marketing products for the global protection of human and animal health. Financial terms were not disclosed. Commenting on the agreement, Ceva Chairman & CEO Dr. Marc Prikazsky said: “From the moment we began talking, it was obvious that with our respective long histories in producing vaccines, we shared a lot of common values through our private, employee and family-owned business structures. Bringing together the two teams will significantly strengthen our biological innovation and development, which is particularly important given the essential role vaccines play in reducing the need for antibiotics, which are critical to the future health of people and animals.”